Evidence remains insufficient to show alpha lipoic acid slows ALS progression
Original source
Alpha Lipoic Acid (opens in a new tab)Alpha lipoic acid has shown potentially helpful effects in preclinical studies, but its benefit for people with ALS remains unclear. An open-label study reported quality-of-life and fatigue improvements with a palladium lipoic acid complex, while motor function was not assessed. A completed clinical trial has not published its results.
Why this matters
People with ALS should not consider alpha lipoic acid an established treatment based on current evidence. The review supports further research, but the available findings do not show that it slows progression or improves motor function in people with ALS.
Limitations and context
This assessment comes from an independent expert review, not a published positive clinical trial. Evidence includes preclinical studies, an open-label study, community reports from people using multiple supplements, and an unpublished trial. Reported benefits from supplement combinations cannot be attributed confidently to alpha lipoic acid. The review says it appeared safe and well tolerated at 600 mg daily in self-reports and trials for other conditions, but this does not establish its effectiveness for ALS.